A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia
NCT ID: NCT05643508
Last Updated: 2022-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
192 participants
INTERVENTIONAL
2022-12-31
2024-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects
NCT03609606
Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers
NCT06758661
A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients
NCT02368613
Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.
NCT04858308
Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506
NCT04874129
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
(D) DWC202206 + DWC202207
(D) DWC202206
Drug of DWC202206 A mg
(D) DWC202207
Drug of DWC202207 B/C mg
(P+D) DWC202206 + DWC202207
(P) DWC202206
Placebo of DWC202206 A mg
(D) DWC202207
Drug of DWC202207 B/C mg
(D+P) DWC202206 + DWC202207
(P) DWC202207
Placebo of DWC202207 B/C mg
(D) DWC202206
Drug of DWC202206 A mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
(P) DWC202206
Placebo of DWC202206 A mg
(P) DWC202207
Placebo of DWC202207 B/C mg
(D) DWC202206
Drug of DWC202206 A mg
(D) DWC202207
Drug of DWC202207 B/C mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with hypertension and hyperlipidemias
Exclusion Criteria
* History of ventricular tachycardia, atrial fibrillation
* Uncontrolled diabetes mellitus
19 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daewoong Pharmaceutical Co. LTD.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DW_DWJ1575301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.